HALO · NASDAQ · Healthcare · Biotechnology

Halozyme Therapeutics

—Past month
Price unavailable
  • 52W range61.23–116.85
  • P/E ratio32.50
  • Market cap12.47B

Latest news

Loading...

About

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables ...

halozyme.com